Farnesyl transferase inhibitors enhance death receptor signals and induce apoptosis in multiple myeloma cells

Leukemia and Lymphoma

Volumn 44, Issue 12, 2003, Pages 2123-2134

  Beaupre, Darrin M ^a   McCafferty Grad, Jennifer ^a   Bahlis, Nizar J ^a   Boise, Lawrence H ^a   Lichtenheld, Mathias G ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Death receptors; Farnesyl transferase inhibitors; Myeloma; Ras

Indexed keywords

CASPASE; CASPASE 3; CASPASE 9; CELL RECEPTOR; FAS LIGAND; INTERLEUKIN 6 RECEPTOR; PERILLIC ACID; PROTEIN BCL XL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; TIPIFARNIB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER RECURRENCE; CELL DEATH; CELL ISOLATION; CELL MEMBRANE DEPOLARIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG SPECIFICITY; ENZYME ACTIVATION; GENE ACTIVITY; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE; MULTIPLE MYELOMA; MYELOMA CELL; PLASMA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ALKYL AND ARYL TRANSFERASES; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-X PROTEIN; BLOTTING, WESTERN; CASPASE 8; CASPASES; CELL CYCLE; CELL DEATH; CELL LINE; CELL LINE, TUMOR; CLINICAL TRIALS; CYCLOHEXENES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; FAS LIGAND PROTEIN; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-6; MEMBRANE GLYCOPROTEINS; MEMBRANE POTENTIALS; MITOCHONDRIA; MONOTERPENES; MUTATION; PLASMA CELLS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 0242489177     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819031000116652     Document Type: Article

References (82)

1. Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. and Bataille, R. (1996) "A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome", N. Engl. J. Med. 335(2), 91-97.
2. Mitsiades, C.S., Treon, S.P., Mitsiades, N., Shima, Y., Richardson, P., Schlossman, R., Hideshima, T. and Anderson, K.C. (2001) "TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications", Blood 98(3), 795-804.
3. Hideshima, T., Richardson, P., Chauhan, D., Palombella, V.J., Elliott, P.J., Adams, J. and Anderson, K.C. (2001) "The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells", Cancer Res. 61(7), 3071-3076.
4. Catlett-Falcone, R., Landowski, T.H., Oshiro, M.M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernandez-Luna, J.L., Nunez, G., Dalton, W.S. and Jove, R. (1999) "Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells", Immunity 10(1), 105-115.
5. Damiano, J.S., Cress, A.E., Hazlehurst, L.A., Shtil, A.A. and Dalton, W.S. (1999) "Cell adhesion mediated drug resistance (CAM-DR : role of integrins and resistance to apoptosis in human myeloma cell lines", Blood 93(5), 1658-1667.
6. Damiano, J.S. and Dalton, W.S. (2000) "Integrin-mediated drug resistance in multiple myeloma", Leuk. Lymphoma 38(1-2), 71-81.
7. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) "Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas", Nature 332(6159), 83-85.
8. Klein, B., Zhang, X.G., Jourdan, M., Content, J., Houssiau, F., Aarden, L., Piechaczyk, M. and Bataille, R. (1989) "Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6", Blood 73(2), 517-526.
9. Klein, B., Zhang, X.G., Jourdan, M., Boiron, J.M., Portier, M., Lu, Z.Y., Wijdenes, J., Brochier, J. and Bataille, R. (1990) "Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma", Eur. Cytokine Netw. 1(4), 193-201.
10. Schwab, G., Siegall, C.B., Aarden, L.A., Neckers, L.M. and Nordan, R.P. (1991) "Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266", Blood 77(3), 587-593.
11. Keller, E.T. and Ershler, W.B. (1995) "Effect of IL-6 receptor antisense oligodeoxynucleotide on in vitro proliferation of myeloma cells", J. Immunol. 154(8), 4091-4098.
12. Ogata, A., Chauhan, D., Tech, G., Treon, S.P., Urashima, M., Schlossman, R.L. and Anderson, K.C. (1997) "IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade", J. Immunol. 159(5), 2212-2221.
13. Hallek, M., Leif Bergsagel, P. and Anderson, K.C. (1998) "Multiple myeloma: increasing evidence for a multistep transformation process", Blood 91(1), 3-21.
14. Kalakonda, N., Rothwell, D.G., Scarffe, J.H. and Norton, J.D. (2001) "Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation", Blood 98(5), 1555-1560.
15. Bezieau, S., Devilder, M.C., Avet-Loiseau, H., Mellerin, M.P., Puthier, D., Pennarun, E., Rapp, M.J., Harousseau, J.L., Moisan, J.P. and Bataille, R. (2001) "High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis", Hum. Mutat. 18(3), 212-224.
16. Futscher, B. and Dalton, W. (1991) "Ras mutations and IL-6 dependence in human myeloma cell lines", Proc. Am. Assoc. Cancer Res. 32, A277.
17. Billadeau, D., Jelinek, D.F., Shah, N., LeBien, T.W. and Van Ness, B. (1995) "Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6", Cancer Res. 55(16), 3640-3646.
18. Boucher, M.J., Morisset, J., Vachon, P.H., Reed, J.C., Laine, J. and Rivard, N. (2000) "MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-XL, and Mcl-1 and promotes survival of human pancreatic cancer cells", J. Cell. Biochem. 79, 355-369.
19. Kinoshita, T., Yokota, T., Arai, K. and Miyajima, A. (1995) "Regulation of Bcl-2 expression by oncogenic Ras protein in hematopoietic cells", Oncogene 10(11), 2207-2212.
20. Harada, N., Hata, H., Yoshida, M., Soniki, T., Nagasaki, A., Kuribayashi, N., Kimura, T., Matsuzaki, H. and Mitsuya, H. (1998) "Expression of Bcl-2 family of proteins in fresh myeloma cells", Leukemia 12(11), 1817-1820.
21. Miguel-Garcia, A., Orero, T., Matutes, E., Carbonell, F., Miguel-Sosa, A., Linares, M., Tarin, F., Herrera, M., Garcia-Talavera, J. and Carbonell-Ramon, F. (1998) "Bcl-2 expression in plasma cells from neoplastic gammopathies and reactive plasmacytosis: a comparative study", Haematologica 83(4), 298-304.
22. Pettersson, M., Jernberg-Wiklund, H., Larsson, L.G., Sundstrom, C., Givol, I., Tsujimoto, Y. and Nilsson, K. (1992) "Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells", Blood 79(2), 495-502.
23. Egle, A., Villunger, A., Marschitz, I., Kos, M., Hittmair, A., Lukas, P., Grunewald, K. and Greil, R. (1997) "Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status", Br. J. Haematol. 97(2), 418-428.
24. Scheid, M.P., Schubert, K.M. and Duronio, V. (1999) "Regulation of bad phosphorylation and association with Bcl-x(L) by the MAPK/Erk kinase", J. Biol. Chem. 274(43), 31108-31113.
25. Khwaja, A., Rodriguez-Viciana, P., Wennstrom, S., Warne, P.H. and Downward, J. (1997) "Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway", EMBO J. 16(10), 2783-2793.
26. Marte, B.M., Rodriguez-Viciana, P., Wennstrom, S., Warne, P.H. and Downward, J. (1997) "R-Ras can activate the phosphoinositide 3-kinase but not the MAP kinase arm ofthe Ras effector pathways", Curr. Biol. 7(1), 63-70.
27. Franke, T.F., Kaplan, D.R. and Cantley, L.C. (1997) "PI3K: downstream AKTion blocks apoptosis", Cell 88(4), 435-437.
28. Zha, J., Harada, H., Yang, E., Jockel, J. and Korsmeyer, S.J. (1996) "Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L) [see comments]", Cell 87(4), 619-628.
29. Del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R. and Nunez, G. (1997) "Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt", Science 278(5338), 687-689.
30. Datta, S.R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y. and Greenberg, M.E. (1997) "Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery", Cell 91(2), 231-241.
31. Hsu, J., Shi, Y., Krajewski, S., Renner, S., Fisher, M., Reed, J.C., Franke, T.F. and Lichtenstein, A. (2001) "The AKT kinase is activated in multiple myeloma tumor cells", Blood 98(9), 2853-2855.
32. Hideshima, T., Nakamura, N., Chauhan, D. and Anderson, K.C. (2001) "Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma", Oncogene 20(42), 5991-6000.
33. Cardone, M.H., Roy, N., Stennicke, H.R., Salvesen, G.S., Franke, T.F., Stanbridge, E., Frisch, S. and Reed, J.C. (1998) "Regulation of cell death protease caspase-9 by phosphorylation", Science 282(5392), 1318-1321.
34. Jackson, J.H., Cochrane, C.G., Bourne, J.R., Solski, P.A., Buss, J.E. (1990) "Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation", Proc. Natl Acad. Sci. USA 87, 3042-3046.
35. Kato, K., Cox, A.D., Hisaka, M.M., Graham, S.M., Buss, J.E. and Der, C.J. (1992) "Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity", Proc. Natl Acad. Sci. USA 89(14), 6403-6407.
36. James, G.L., Brown, M.S., Cobb, M.H. and Goldstein, J.L. (1994) "Benzodiazepine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in H-Ras-transformed Rat-1 cells, but not in untransformed cells", J. Biol. Chem. 269(44), 27705-27714.
37. Gana-Weisz, M., Haklai, R., Marciano, D., Egozi, Y., Ben-Baruch, G. and Kloog, Y. (1997) "The Ras antagonist S-farnesylthiosalicylic acid induces inhibition of MAPK activation", Biochem. Biophys. Res. Commun. 239(3), 900-904.
38. End, D.W. (1999) "Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway", Investig. New Drugs 17(3), 241-258.
39. Sebti, S.M. and Hamilton, A.D. (2000) "Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies", Oncogene 19(56), 6584-6593.
40. Yan, N., Ricca, C., Fletcher, J., Glover, T., Seizinger, B.R. and Manne, V. (1995) "Farnesyltransferase inhibitors block the neurofibromatosis type I(NF1) malignant phenotype", Cancer Res. 55(16), 3569-3575.
41. End, D.W., Smets, G., Todd, A.V., Applegate, T.L., Fuery, C.J., Angibaud, P., Venet, M., Sanz, G., Poignet, H., Skrzat, S., Devine, A., Wouters, W. and Bowden, C. (2001) "Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro", Cancer Res. 61(1), 131-137.
42. Haag, J.D. and Gould, M.N. (1994) "Mammary carcinoma regression induced by perillyl alcohol, a hydroxylated analog of limonene", Cancer Chemother. Pharmacol. 34(6), 477-483.
43. Mills, J.J., Chari, R.S., Boyer, I.J., Gould, M.N. and Jirtle, R.L. (1995) "Induction of apoptosis in liver tumors by the monoterpene perillyl alcohol", Cancer Res. 55(5), 979-983.
44. Stark, M.J., Burke, Y.D., McKinzie, J.H., Ayoubi, A.S. and Crowell, P.L. (1995) "Chemotherapy of pancreatic cancer with the monoterpene perillyl alcohol", Cancer Lett. 96(1), 15-21.
45. Ripple, G.H., Gould, M.N., Stewart, J.A., Tutsch, K.D., Arzoomanian, R.Z., Alberti, D., Feierabend, C., Pomplun, M., Wilding, G. and Bailey, H.H. (1998) "Phase I clinical trial of perillyl alcohol administered daily", Clin. Cancer Res. 4(5), 1159-1164.
46. Ripple, G.H., Gould, M.N., Arzoomanian, R.Z., Alberti, D., Feierabend, C., Simon, K., Binger, K., Tutsch, K.D., Pomplun, M., Wahamaki, A., Marnocha, R., Wilding, G. and Bailey, H.H. (2000) "Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day", Clin Cancer Res. 6(2), 390-396.
47. Karp, J.E., Lancet, J.E., Kaufmann, S.H., End, D.W., Wright, J.J., Bol, K., Horak, I., Tidwell, M.L., Liesveld, J., Kottke, T.J., Ange, D., Buddharaju, L., Gojo, I., Highsmith, W.E., Belly, R.T., Hohl, R.J., Rybak, M.E., Thibault, A. and Rosenblatt, J. (2001) "Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial", Blood 97(11), 3361-3369.
48. Grad, J.M., Bahlis, N.J., Reis, I., Oshiro, M.M., Dalton, W.S. and Boise, L.H. (2001) "Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells", Blood 98(3), 805-813.
49. Dalton, W.S., Durie, B.G., Alberts, D.S., Gerlach, J.H. and Cress, A.E. (1986) "Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein", Cancer Res. 46(10 , 5125-5130.
50. Crowell, P.L., Ren, Z., Lin, S., Vedejs, E. and Gould, M.N. (1994) "Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation", Biochem. Pharmacol. 47(8), 1405-1415.
51. Hengartner, M.O. (2000) "The biochemistry of apoptosis", Nature 407(12), 770-776.
52. Chen, Q., Gong, B., Mahmoud-Ahmed, A.S., Zhou, A., Hsi, E.D., Hussein, M. and Almasan, A. (2001) "Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma", Blood 98(7), 2183-2192.
53. Ashkenazi, A. and Dixit, V.M. (1998) "Death receptors: signaling and modulation", Science 281(5381), 1305-1308.
54. Suzuki, N., Urano, J. and Tamanoi, F. (1998) "Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells", Proc. Natl Acad. Sci. USA 95(26), 15356-15361.
55. Mazzocca, A., Giusti, S., Hamilton, A.D., Sebti, S.M., Pantaleo, P. and Carloni, V. (2003) "Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines", Mol. Pharmacol. 63(1), 159-166.
56. Gauthier, E.R., Piche, L., Lemieux, G. and Lemieux, R. (1996) "Role of bcl-X(L) in the control of apoptosis in murine myeloma cells", Cancer Res. 56(6), 1451-1456.
57. Tu, Y., Renner, S., Xu, F., Fleishman, A., Taylor, J., Weisz, J., Vescio, R., Rettig, M., Berenson, J., Krajewski, S., Reed, J.C. and Lichtenstein, A. (1998) "BCL-X expression in multiple myeloma: possible indicator of chemoresistance", Cancer Res. 58(2), 256-262.
58. Bonavida, B., Ng, C.P., Jazirehi, A., Schiller, G. and Mizutani, Y. (1999) "Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics (Review)", Int. J. Oncol. 15(4), 793-802.
59. Jazirehi, A.R., Ng, C.P., Gan, X.H., Schiller, G. and Bonavida, B. (2001) "Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis", Clin. Cancer Res. 7(12), 3874-3883.
60. Landowski, T.H., Gleason-Guzman, M.C. and Dalton, W.S. (1997) "Selection for drug resistance results in resistance to Fas-mediated apoptosis", Blood 89(6), 1854-1861.
61. Landowski, T.H., Shain, K.H., Oshiro, M.M., Buyuksal, I., Painter, J.S. and Dalton, W.S. (1999) "Myeloma cells selected for resistance to CD95-mediated apoptosis are not cross-resistant to cytotoxic drugs: evidence for independent mechanisms of caspase activation", Blood 94(1), 265-274.
62. Shima, Y., Nishimoto, N., Ogata, A., Fujii, Y., Yoshizaki, K. and Kishimoto, T. (1995) "Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis", Blood 85(3), 757-764.
63. Shima, Y., Nishimoto, N., Yoshizaki, K. and Kishimoto, T. (1996) "Fas antigen/APO-1 (CD95) expression on myeloma cells", Leuk. Lymphoma 23(5-6), 521-531.
64. Hata, H., Matsuzaki, H., Takeya, M., Yoshida, M., Sonoki, T., Nagasaki, A., Kuribayashi, N., Kawano, F. and Takatsuki, K. (1995) "Expression of Fas/Apo-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders", Blood 86(5), 1939-1945.
65. Westendorf, J.J., Lammert, J.M. and Jelinek, D.F. (1995) "Expression and function of Fas (APO-1/CD95) inpatient myeloma cells and myeloma cell lines", Blood 85(12), 3566-3576.
66. Jennings, C.D. and Foon, K.A. (1997) "Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy", Blood 90(8), 2863-2892.
67. Downward, J. (1997) "Cell cycle: routine role for Ras", Curr. Biol. 7(4), R258-R260.
68. Cai, H., Szeberenyi, J. and Cooper, G.M. (1990) "Effect of a dominant inhibitory Ha-ras mutation on mitogenic signal transduction in NIH 3T3 cells", Mol. Cell. Biol. 10(10), 5314-5323.
69. Feig, L.A. and Cooper, G.M. (1988) "Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP", Mol. Cell Biol. 8(8), 3235-3243.
70. Mulcahy, L.S., Smith, M.R. and Stacey, D.W. (1985) "Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells", Nature 313(5999), 241-243.
71. Kerkhoff, E. and Rapp, U.R. (1998) "Cell cycle targets of Ras/Raf signalling", Oncogene 17(11 Reviews), 1457-1462.
72. Gabrea, A., Bergsagel, P.L., Chesi, M., Shoo, Y. and Kuehl, W.M. (1999) "Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell", Mol. Cell. 3(1), 119-123.
73. Kip1 deregulation and anitestrogen resistance in human breast cancer cells, J. Biol. Chem. 276(44), 40888-40895.
74. Law, B.K., Norgaard, P., Gnudi, L., Kahn, B.B., Poulson, H.S. and Moses, H.L. (1999) "Inhibition of DNA synthesis by a farnesyltransferase inhibitor involves inhibition of the p70(s6k) pathway", J. Biol. Chem. 274(8), 4743-4748.
75. Law, B.K., Norgaard, P. and Moses, H.L. (2000) "Farnesyltransferase inhibitor induces rapid growth arrest and blocks p70s6k activation by multiple stimuli", J. Biol. Chem. 275(15), 10796-10801.
76. Laurent, G. and Jaffrezou, J.P. (2001) "Signaling pathways activated by daunorubicin", Blood 98(4), 913-924.
77. Zhang, B., Prendergast, G.C. and Fenton, R.G. (2002) "Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression", Cancer Res. 62(2), 450-458.
78. David, M. (1995) "Requirement for MAP kinase (ERK2) activity in interferon alpha- and interferon beta-stimulated gene expression through STAT proteins [see comments]", Science 269(5231), 1721-1723.
79. Puthier, D., Bataille, R. and Amiot, M. (1999) "IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway", Eur. J. Immunol. 29(12), 3945-3950.
80. Derenne, S., Monia, B., Dean, N.M., Taylor, J.K., Rapp, M.J., Harousseau, J.L., Bataille, R. and Amiot, M. (2002) "Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells", Blood 100(1), 194-199.
81. Gelb, M.H., Tamanoi, F., Yokoyama, K., Ghomashchi, F., Esson, K. and Gould, M.N. (1995) "The inhibition of protein prenyltransferases by oxygenated metabolites of limonene and perillyl alcohol", Cancer Lett. 91(2), 169-175.
82. Le Gouill, S., Pellat-Deceunynck, C., Harousseau, J.L., Rapp, M.J., Robillard, N., Bataille, R. and Amiot, M. (2002) "Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells", Leukemia 16, 1664-1667.